BridgeBio Oncology Therapeutics Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a BBOT research report →
Range $23 – $23
Price Chart
About the company
BridgeBio Oncology Therapeutics functions as a clinical-stage biopharmaceutical firm dedicated to pioneering advanced small molecule treatments. These therapies are aimed at combating malignancies driven by RAS and PI3Kα, both frequently encountered oncogenes in human cancers. Initially established as an offshoot of BridgeBio Pharma, the company concentrates on precision oncology.
- CEO
- Pedro J. Beltran
- IPO
- 2025
- Employees
- 92
- HQ
- South San Francisco, CA, US
Get TickerSpark's AI analysis on BBOT
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $727.37M
- P/E
- -0.01
- PEG
- 0.00
- P/S
- 0.00
- P/B
- 0.00
- EV/EBITDA
- -3.47
- Div Yield
- 0.00%
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -46.90%
- ROIC
- -61.10%
Latest fiscal year · YoY change
- Revenue
- $0+0.0%
- Gross Profit
- $0+0.0%
- Op Income
- $-145,819,000
- Net Income
- $-134,044,000-80.5%
- EPS
- $-4.30-1034.8%
- OCF Growth
- -14811.1%
- FCF Growth
- -14890.4%
- 52W High
- $14.87
- 52W Low
- $7.00
- 50D MA
- $8.38
- 200D MA
- $9.99
- Beta
- 0.36
- RSI (14)
- 53
- Avg Volume
- 389.66K
No earnings-call transcripts are available for BBOT yet.
- Free Float
- 0.6%
- Shares Outstanding
- 80.11M
- Float Shares
- 452.99K
of shares held by institutions
53 13F filers
Buy/sell ratio 3.00. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Vanguard Group Inc | 791.10K | ▲ 143.50K |
| Cibc Private Wealth Group, LLC | 5.00K | ▲ 5.00K |
Held by 36 ETFs
Biggest fund positions in BBOT by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Jul 1, 26 | Cobo Marc | other | 125 |
| Jul 1, 26 | Elmelech Idan | other | 343 |
| Jul 1, 26 | Ben Yong | other | 1,047 |
| Jul 1, 26 | Beltran Pedro | other | 1,047 |
| Jul 1, 26 | Chen Bihua | other | 130,865 |
| Jul 1, 26 | Chen Bihua | other | 1,704,862 |
| Jul 1, 26 | Chen Bihua | other | 2,692,459 |
| Jul 1, 26 | Chen Bihua | other | 4,528,186 |
| Jun 16, 26 | Tipirneni Praveen P. | other | 31,675 |
| Jun 16, 26 | MCCORMICK FRANK | other | 31,675 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our BBOT coverage
Recent articles, reports, and earnings notes.
No research on BBOT yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate BBOT report →BridgeBio Oncology Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
globenewswire.com · Aug 11
BBOT Reports Second Quarter 2026 Financial Results and Update on Corporate Progress
globenewswire.com · Aug 11
BridgeBio Oncology Therapeutics, Inc (NASDAQ:BBOT) Receives $24.80 Average PT from Brokerages
defenseworld.net · Jul 28
BridgeBio Oncology Therapeutics: KRAS Program Data Due 2H26 May Reignite Bullish Sentiment
seekingalpha.com · Jul 13
BBOT Reports First Quarter 2026 Financial Results and Update on Corporate Progress
globenewswire.com · May 12
BridgeBio Oncology Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
globenewswire.com · May 12
Here Are Monday’s Top Wall Street Analyst Research Calls: Dell Technologies, BioMarin Pharmaceutical, Disney, HubSpot, Klarna, Oklo, Pitney Bowes, Trade Desk, Wendy’s, and More
247wallst.com · May 11
BBOT Presents Preclinical Data Demonstrating pan-KRAS Inhibitor BBO-11818 Has Robust Anti-Tumor Activity in KRAS-Mutant Preclinical Models at the AACR Annual Meeting 2026
globenewswire.com · Apr 22
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.